Cargando…

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody kinetics after BNT162B2 vaccination

Detalles Bibliográficos
Autores principales:	Hettiarachchi, Ravin, Naidu, Kartik, Payne, Suzanne, Holland, Juliette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810227/ http://dx.doi.org/10.1016/j.pathol.2021.12.104

Ejemplares similares

Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine
por: Ferrari, Davide, et al.
Publicado: (2021)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

Kinetics and persistence of anti‐SARS‐CoV‐2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort
por: Šošić, Lara, et al.
Publicado: (2021)

Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2
por: Clairon, Quentin, et al.
Publicado: (2023)

Serum antibody response to BNT162b2 after natural SARS‐CoV‐2 infection
por: Perkmann, Thomas, et al.
Publicado: (2021)

Transplacental transfer of SARS-CoV-2 antibodies in recovered and BNT162b2-vaccinated patients
por: Treger, Sharon, et al.
Publicado: (2022)

Population differences in antibody response to SARS‐CoV‐2 infection and BNT162b2 vaccination
por: Shapira, Guy, et al.
Publicado: (2022)

Reduced BNT162b2 Messenger RNA Vaccine Response in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Naive Nursing Home Residents
por: Canaday, David H, et al.
Publicado: (2021)

Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals
por: Maeda, Kenji, et al.
Publicado: (2021)

Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
por: Maeda, Kenji, et al.
Publicado: (2021)

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
por: Manisty, Charlotte, et al.
Publicado: (2021)

Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
por: Wang, Bei, et al.
Publicado: (2021)

Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis
por: Yau, Kevin, et al.
Publicado: (2021)

Limited Neutralization of Omicron by Antibodies from the BNT162b2 Vaccination against SARS-CoV-2
por: Lanz, Tobias V., et al.
Publicado: (2022)

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals
por: Muena, Nicolás A., et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

An Association Study of HLA with the Kinetics of SARS-CoV-2 Spike Specific IgG Antibody Responses to BNT162b2 mRNA Vaccine
por: Khor, Seik-Soon, et al.
Publicado: (2022)

Amplitudes and kinetic of antibodies after second and third doses of BNT162b2 vaccine in nonagenarians and centenarians with and without prior SARS-CoV-2 infection
por: Tuaillon, Edouard, et al.
Publicado: (2022)

Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
por: Montoya, José G., et al.
Publicado: (2021)

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors
por: Tan, Chee-Wah, et al.
Publicado: (2021)

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination
por: Iketani, Sho, et al.
Publicado: (2021)

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
por: Ebinger, Joseph E., et al.
Publicado: (2021)

Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
por: Hatzakis, Angelos, et al.
Publicado: (2022)

Longitudinal Analysis of Antiphospholipid Antibody Dynamics after Infection with SARS-CoV-2 or Vaccination with BNT162b2
por: Ogrič, Manca, et al.
Publicado: (2022)

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021)

SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays
por: Padoan, Andrea, et al.
Publicado: (2021)

Kinetics of Anti-Sars-Cov-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes
por: Karavani, Gilad, et al.
Publicado: (2022)

Anti–severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination
por: Kelly, Jeannie C., et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

The effect of the BNT162b2 vaccine on antinuclear antibody and antiphospholipid antibody levels
por: Noureldine, Hussein A., et al.
Publicado: (2022)

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers
por: Terpos, Evangelos, et al.
Publicado: (2021)

SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore
por: Lau, Chin Shern, et al.
Publicado: (2022)

Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 vaccine
por: Ferrari, Davide, et al.
Publicado: (2022)

SARS-CoV-2 Antibody Response to the BNT162b2 mRNA Vaccine in Persons with Past Natural Infection
por: Kang, Yu Min, et al.
Publicado: (2021)

Early Onset of SARS-COV-2 Antibodies after First Dose of BNT162b2: Correlation with Age, Gender and BMI
por: Pellini, Raul, et al.
Publicado: (2021)

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination
por: Jo, Dong-Ho, et al.
Publicado: (2021)

Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine
por: Schwartz, Anat, et al.
Publicado: (2021)

Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2
por: Salvaggio, Marcello, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fl8dt3don3rlnig6hqt098mqcq